Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 -- G1 Therapeutics, Inc. , a commercial-stage oncology company, today announced the presentation of four posters that provide new-real world evidence...

Related Keywords

Tennessee ,United States ,Boston ,Massachusetts ,American ,Trilaciclib Huang ,Raj Malik ,American Society Of Clinical Oncology ,Nasdaq ,Community Oncology Setting Goldschmidt ,Globenewswire Inc ,Therapeutics Inc ,Linkedin ,Research Triangle Park ,Community Oncology Practices Gajra ,Us Oncology Network ,Exchange Commission ,Investor Relations Corporate Communications ,Clinical Oncology ,Quality Care Symposium ,Chief Medical Officer ,Healthcare Utilization Among Patients ,Community Oncology Practices ,Cytopenia Events Among Patients ,Extensive Stage Small Cell ,Medicare Fee For Service ,Retrospective Analysis ,Real World Data ,Tennessee Oncology ,Characteristics Associated ,Myelosuppression Among Patients ,Extensive Stage Small Cell Lung Cancer Treated ,Community Oncology Setting ,Triangle Park ,Private Securities Litigation Reform Act ,Investor Relations ,Markets ,